Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase II trial studies how well avelumab with or without cetuximab work in treating
patients with skin squamous cell cancer that has spread to other places in the body.
Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread.
-
Click here for details...
This phase III trial studies how well pembrolizumab works compared to standard of care
observation in treating patients with stage I-III Merkel cell cancer that has been completely
removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread.
-
Click here for details...
This phase II trial studies how well encorafenib and binimetinib work before surgery in
treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph
nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission
tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to
encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and
CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib
may provide more information on melanoma over time.
-
Click here for details...
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment
of dabrafenib and trametinib works to overcome resistance and delay disease progression in
treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause
cell death in tumor cells that rely on a process called "autophagy" for survival. Dabrafenib
and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work
better than dabrafenib and trametinib alone to shrink and stabilize the cancer.
-
Click here for details...
This phase II trial investigates how well biomarkers on PET/CT imaging drive early
discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be
removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for
patients with unresectable melanoma. This trial is being done to determine if doctors can
safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers
seen on PET/CT imaging and tumor biopsy.
-
Click here for details...
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001
in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy
with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with
the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could
improve the ability of the immune system to shrink tumors and to prevent them from returning.
-
Click here for details...
Patients with a primary invasive melanoma are recommended to undergo excision of the primary
lesion with a wide margin. There is evidence that less radical margins of excision may be
just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of
the primary lesion for adult patients with stage II primary invasive cutaneous melanomas
(AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins
is expected to improve patient quality of life.
|
